Changes in Lipid Profiles After Switching to a Protease Inhibitor-containing CART--unfavourable Effect of Fosamprenavir in Obese Patients

Overview

Journal Eur J Med Res

Publisher Biomed Central

Specialty General Medicine

Date 2011 Apr 6

PMID 21463988

Citations 2

Authors

Miriam Gyalrong-Steur

J R Bogner

U Seybold

Affiliations

Soon will be listed here.

Abstract

Objective: One focus in the medical care of HIV-infected patients today is cardiovascular risk reduction. Metabolic disturbances occur frequently in patients taking protease inhibitors (PI) and are a major risk factor for atherosclerosis. With few published head-to-head studies substance-specific differences concerning metabolic effects are insufficiently defined. Therefore this cohort study directly compared the metabolic profiles of boosted atazanavir (ATV/r), fosamprenavir (FPV/r) and saquinavir (SQV/r).

Methods: Data from a cohort of 124 HIV patients initiating a boosted regimen with one of the PIs at the University of Munich (LMU) infectious diseases outpatient clinic were retrospectively analyzed. The main outcome measures were median absolute total cholesterol levels and median relative change of total cholesterol levels after six months of PI-therapy. A multivariate linear regression model was built to identify and control for potential confounders of the association between PI-therapy and serum cholesterol level.

Results: 84 patients were treated with ATV/r, 23 patients received FPV/r and 17 patients SQV/r. Demographically the cohort constituted a representative sample of HIV-infected patients in Germany. There were no statistically significant differences between the comparison groups at baseline. - After six months of therapy median serum cholesterol in the ATV/r group dropped significantly from 204 mg/dl to 186 mg/dl, while in the FPV/r and SQV/r groups a rise in serum cholesterol levels was observed from 179 mg/dl to 204 mg/dl and from 173 mg/dl to 209 mg/dl respectively. The multivariate linear regression model identified a significant interaction between BMI at baseline and treatment with FPV/r: patients with higher BMI showed more prominent increases in serum cholesterol while taking FPV/r compared to patients with lower BMI.

Conclusion: This cohort study demonstrated the most favourable impact on serum cholesterol levels and thus cardiovascular risk for ATV/r compared to FPV/r and SQV/r under real-life conditions. Given the statistical interaction detected between FPV/r and BMI further studies assessing metabolic profiles of different antiretroviral drugs in specific patient populations are urgently needed.

Citing Articles

Antiretroviral Therapy-Induced Dysregulation of Gene Expression and Lipid Metabolism in HIV+ Patients: Beneficial Role of Antioxidant Phytochemicals.

Jimenez-Osorio A, Jaen-Vega S, Fernandez-Martinez E, Ortiz-Rodriguez M, Martinez-Salazar M, Jimenez-Sanchez R Int J Mol Sci. 2022; 23(10).

PMID: 35628408 PMC: 9146859. DOI: 10.3390/ijms23105592.

[HIV infection : chronic disease with comorbidities].

Bogner J Internist (Berl). 2012; 53(10):1169-78.

PMID: 22986542 DOI: 10.1007/s00108-011-2972-7.

References

Friis-Moller N, Reiss P, Sabin C, Weber R, Monforte A, El-Sadr W . Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007; 356(17):1723-35. DOI: 10.1056/NEJMoa062744. View

Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, Monforte A . Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS. 2003; 17(8):1179-93. DOI: 10.1097/01.aids.0000060358.78202.c1. View

Fontas E, van Leth F, Sabin C, Friis-Moller N, Rickenbach M, dArminio Monforte A . Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?. J Infect Dis. 2004; 189(6):1056-74. DOI: 10.1086/381783. View

Alberti K, Zimmet P, Shaw J . The metabolic syndrome--a new worldwide definition. Lancet. 2005; 366(9491):1059-62. DOI: 10.1016/S0140-6736(05)67402-8. View

Molina J, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N . Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008; 372(9639):646-55. DOI: 10.1016/S0140-6736(08)61081-8. View

Kung H, Hoyert D, Xu J, Murphy S . Deaths: final data for 2005. Natl Vital Stat Rep. 2008; 56(10):1-120. View

Dube M, Stein J, Aberg J, Fichtenbaum C, Gerber J, Tashima K . Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the.... Clin Infect Dis. 2003; 37(5):613-27. DOI: 10.1086/378131. View

Periard D, Telenti A, Sudre P, Cheseaux J, Halfon P, Reymond M . Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation. 1999; 100(7):700-5. DOI: 10.1161/01.cir.100.7.700. View

Baigent C, Keech A, Kearney P, Blackwell L, Buck G, Pollicino C . Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366(9493):1267-78. DOI: 10.1016/S0140-6736(05)67394-1. View

10.

Dragsted U, Gerstoft J, Youle M, Fox Z, Losso M, Benetucci J . A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. Antivir Ther. 2005; 10(6):735-43. View

11.

Thompson M, Aberg J, Cahn P, Montaner J, Rizzardini G, Telenti A . Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010; 304(3):321-33. DOI: 10.1001/jama.2010.1004. View

12.

Crum N, Riffenburgh R, Wegner S, Agan B, Tasker S, Spooner K . Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr. 2006; 41(2):194-200. DOI: 10.1097/01.qai.0000179459.31562.16. View

13.

Friis-Moller N, Sabin C, Weber R, Monforte A, El-Sadr W, Reiss P . Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003; 349(21):1993-2003. DOI: 10.1056/NEJMoa030218. View

14.

. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285(19):2486-97. DOI: 10.1001/jama.285.19.2486. View

15.

De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J . European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003; 24(17):1601-10. DOI: 10.1016/s0195-668x(03)00347-6. View

16.

Lafeuillade A, Hittinger G, Philip G, Lambry V, Jolly P, Poggi C . Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra). HIV Clin Trials. 2005; 5(6):392-8. DOI: 10.1310/Q0TG-0V50-9JML-638U. View

17.

Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P . Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002; 346(26):2039-46. DOI: 10.1056/NEJMoa012354. View

18.

Manfredi R, Chiodo F . Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J Infect. 2001; 42(3):181-8. DOI: 10.1053/jinf.2001.0829. View

19.

Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J . Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007; 370(9602):1829-39. DOI: 10.1016/S0140-6736(07)61778-4. View

20.

Clumeck N, Pozniak A, Raffi F . European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med. 2008; 9(2):65-71. DOI: 10.1111/j.1468-1293.2007.00533.x. View